887752-13-8

Basic information

• Product Name: 7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid
• Synonyms: 7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid
• CAS NO: 887752-13-8
• Molecular Formula: C₂₂H₃₄O₄
• Molecular Weight: 362.50296
• Mol File: 887752-13-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid(887752-13-8)
• EPA Substance Registry System: 7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid(887752-13-8)

Safety Data

• Hazardous Substances Data: 887752-13-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid is used as a potential anti-inflammatory agent for its expected similarity to the potent anti-inflammatory activities of Protectin D1. Its role in modulating inflammation and immune responses could make it a promising candidate for the development of therapeutics targeting various inflammatory conditions.
Used in Research Applications:
In the field of biological research, 7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid serves as a valuable compound for studying the biological activity and mechanisms of action of docosanoids. This can contribute to a better understanding of the roles these molecules play in inflammation and other physiological processes, potentially leading to the discovery of new therapeutic targets and treatments.

Upstream product

• 2234-74-4 docosa-7Z,10Z,13Z,16Z,19Z-pentaenoic acid 

Relevant articles and documents

Controlled formation of mono- and dihydroxy-resolvins from EPA and DHA using soybean 15-lipoxygenase

Resolvins and protectins are important anti-infl ammatory and pro-resolution compounds derived from the enzymatic oxidation of omega-3 fatty acids all -cis -5,8,11,14,17- eicosapentaenoic acid (EPA) and all -cis -4,7,10,13,16,19-docosahexaenoic acid (DHA). We have developed a simple, controlled method to synthesize an array of resolvin and protectin analogs from fatty acid starting materials using soybean 15-lipoxygenase. The conditions were optimized for the production of both mono- and dihydroxy derivatives, with enzyme concentration and pH found to have a signifi cant effect on the reaction products. The methods were applied to fi ve biologically important omega-3 and omega-6 fatty acid substrates. Mono- and dihydroxy compounds were successfully synthesized from all substrates and the products were characterized by normal phase (NP) HPLC , GC-MS, TOF-MS, UV-visible (UV-vis) spectroscopy, and NMR spectroscopy. The methods could be further applied to any polyunsaturated fatty acids containing the cis -1,4,7,10-undecatetraene moiety to produce a range of novel compounds with potential biological activity. Copyright

OXYLIPINS FROM LONG CHAIN POLYUNSATURATED FATTY ACIDS AND METHODS OF MAKING AND USING THE SAME

Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.